Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEEBACIN vs INH
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
Treatment of tuberculosis (first-line therapy in combination with other antituberculosis agents)
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
1350 mg orally twice daily with food.
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; clinical context: reduced dosing interval required in renal impairment (e.g., every 12-24 hours for Cr Cl <30 m L/min)
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
Isoniazid is metabolized primarily by N-acetyltransferase 2 (NAT2) in the liver. Rifampin is metabolized via deacetylation and undergoes extensive enterohepatic circulation; it is a potent inducer of CYP3A4 and other CYP450 enzymes.
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal elimination (10-20%)
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
10-20% bound, primarily to albumin
0-10% (low binding; primarily albumin).
0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
Oral: 75-90%; bioavailability decreases with food intake
Oral: ~90%. Intramuscular: ~100%.
GFR ≥60 m L/min: no adjustment; GFR 30-59: 1350 mg once daily; GFR 15-29: 1350 mg every 48 hours; GFR <15 or dialysis: not recommended.
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
Child-Pugh A: no adjustment; Child-Pugh B: 1350 mg once daily; Child-Pugh C: not recommended.
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Not established; safety and efficacy not evaluated.
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
Start at 1350 mg once daily; monitor renal function; increase to twice daily if tolerated and Cr Cl ≥60 m L/min.
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
Severe and sometimes fatal hepatitis has been reported with isoniazid. Risk is increased in patients with pre-existing liver disease, daily alcohol use, or concurrent use of other hepatotoxic drugs.
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
Hepatotoxicity (monitor liver function); peripheral neuropathy (pyridoxine supplementation recommended); hypersensitivity reactions; rifampin may cause reddish discoloration of body fluids; drug interactions due to CYP450 induction.
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
Hypersensitivity to isoniazid, rifampin, or any component; severe hepatic damage; acute liver disease; history of isoniazid-associated hepatotoxicity.
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as it may cause hypertensive crisis. Take with food to reduce gastrointestinal upset. Avoid tyramine-rich foods like soy products and sauerkraut.
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects based on animal studies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment due to drug-induced vasoconstriction.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
Unknown if TEEBACIN is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and growth retardation, breastfeeding is not recommended. M/P ratio not available.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
No dosing recommendations for use in pregnancy as drug is contraindicated. If used inadvertently, pharmacokinetic changes include increased renal clearance in later pregnancy, which may reduce drug exposure. However, due to teratogenicity, no dose adjustment is advised; immediate discontinuation upon pregnancy detection is recommended.
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
Monitor liver function tests (ALT, AST) monthly due to risk of hepatotoxicity. Avoid use in patients with porphyria as it may precipitate acute attacks. Contraindicated in pregnancy (Pregnancy Category X). Administer with pyridoxine (vitamin B6) to reduce peripheral neuropathy risk.
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
Take this medication exactly as prescribed; do not skip doses or stop early without consulting your doctor.,Avoid alcohol completely while taking this drug due to increased risk of liver damage.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe nausea/vomiting, or abdominal pain.,Use effective contraception if you are of childbearing age; this drug can cause severe birth defects.,Take vitamin B6 supplements as directed to help prevent numbness or tingling in hands and feet.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEEBACIN vs INH, answered by our medical review team.
TEEBACIN is a Antitubercular agent that works by TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.. INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEEBACIN and INH depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEEBACIN is: 1350 mg orally twice daily with food.. The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEEBACIN and INH in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEEBACIN is classified as Category C. TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial de. INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.